2016. EULAR Annual Congress – First and Second Line Treatment Persistence Among Patients with Immune Mediated Rheumatoid Disease Treated with Subcutaneous TNF-Alpha Inhibitors

Dalen J, Svedbom A, Black CM, Kachroo S. First and Second Line Treatment Persistence Among Patients with Immune Mediated Rheumatoid Disease Treated with Subcutaneous TNF-Alpha Inhibitors. Ann Rheum Dis. 2016;75(Suppl2):877. Presented at: EULAR 2016; June 8-11, 2016; London, UK.